Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Gamida Cell ltd
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brown University
Pfizer
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Massachusetts General Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Thomas Jefferson University
City of Hope Medical Center
Ipsen
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Takeda
National Institutes of Health Clinical Center (CC)
Columbia University
Pfizer
SCRI Development Innovations, LLC
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Rutgers, The State University of New Jersey
University of Pennsylvania
Bristol-Myers Squibb
Fate Therapeutics
Karyopharm Therapeutics Inc
Fred Hutchinson Cancer Center
Molecular Templates, Inc.
Kiadis Pharma